腹腔镜与开腹远端胃切除术治疗局部进展期胃癌的五年结局:CLASS-01随机临床试验
CLASS-01非劣效性随机试验在14个中国中心纳入1056例cT2-T4a无大块淋巴结或远处转移的胃癌患者,1:1随机接受腹腔镜或开腹远端胃切除加D2淋巴结清扫。
要点
- 局部进展期胃癌腹腔镜远端胃切除加D2清扫的5年总生存不劣于开腹手术。
- 5年总生存率腹腔镜组72.6% vs 开腹组76.3%,差异无统计学意义。
- 胃癌相关死亡和其他原因死亡在两组间均无显著差异。
核心结论
- 由高流量专科机构经验丰富外科医生实施的腹腔镜远端胃切除加D2淋巴结清扫,治疗局部进展期胃癌的5年总生存与开腹远端胃切除相似。
研究设计与样本
- 非劣效、开放标签、随机临床试验,中国14个中心,2012年9月12日至2014年12月3日入组,最终随访2019年12月31日。
- 纳入1056例临床分期T2、T3或T4a、无大块淋巴结或远处转移的胃癌患者,按部位、年龄、分期和组织学分层后1:1随机。
- 腹腔镜远端胃切除组528例,开腹远端胃切除组528例,均行D2淋巴结清扫。
- 主要分析基于意向性治疗,另进行符合方案和按实际治疗分析。
- 共1039例接受治愈性治疗的患者纳入分析(男性726例[69.9%];平均[SD]年龄56.2[10.7]岁)。
主要发现
- 各肿瘤分期的总生存率在两组间均无显著差异。
临床怎么用
- 在具备经验的中心和经过选择的地方进展期胃癌患者中,腹腔镜远端胃切除加D2淋巴结清扫可作为开腹手术的替代选择。
局限性
- 研究在中国14个高流量专科中心由经验丰富外科医生实施,结果外推到低流量中心或经验较少术者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: It is not clear whether laparoscopic and open distal gastrectomy produce similar outcomes among patients with locally advanced gastric cancer. Data from a multicenter, randomized clinical trial (Chinese Laparoscopic Gastrointestinal Surgical Study [CLASS]-01) showed that laparoscopic distal gastrectomy did not result in inferior disease-free survival at 3 years compared with open distal gastrectomy. OBJECTIVE: To report 5-year overall survival data from the CLASS-01 trial of laparoscopic vs open distal gastrectomy among patients with locally advanced gastric cancer. DESIGN, SETTING, AND PATIENTS: This was a noninferiority, open-label, randomized clinical trial conducted at 14 centers in China. A total of 1056 eligible patients with clinical stage T2, T3, or T4a gastric cancer without bulky nodes or distant metastases were enrolled from September 12, 2012, to December 3, 2014. Final follow-up was on December 31, 2019. INTERVENTIONS: Participants were randomized in a 1:1 ratio after stratification by site, age, cancer stage, and histologic features to undergo either laparoscopic distal gastrectomy (n = 528) or open distal gastrectomy (n = 528) with D2 lymphadenectomy. MAIN OUTCOMES AND MEASURES: The 5-year overall survival rates were updated to compare laparoscopic distal gastrectomy with open distal gastrectomy. All analyses were performed on an intention-to-treat basis. In addition, per-protocol and as-treated analyses were performed for overall survival. RESULTS: Data from 1039 patients (726 men [69.9%]; mean [SD] age, 56.2 [10.7] years) who received curative therapy were analyzed. At 5 years, the overall survival rates were 72.6% in the laparoscopic distal gastrectomy group and 76.3% in the open distal gastrectomy group (log-rank P = .19; hazard ratio, 1.17; 95% CI, 0.93-1.48; P = .19). After comparison for competing risk events, gastric cancer-related deaths (hazard ratio, 1.14; 95% CI, 0.87-1.49; P = .34) and deaths from other causes (hazard ratio, 1.23; 95% CI, 0.74-2.05; P = .42) did not differ significantly between groups. Overall rates of survival did not differ significantly between groups with each tumor stage. CONCLUSIONS AND RELEVANCE: This study found that laparoscopic distal gastrectomy with D2 lymphadenectomy performed by experienced surgeons in high-volume specialized institutions resulted in similar 5-year overall survival compared with open distal gastrectomy among patients with locally advanced gastric cancer. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01609309.
引用
- Huang C, Liu H, Hu Y, et al. Laparoscopic vs Open Distal Gastrectomy for Locally Advanced Gastric Cancer: Five-Year Outcomes From the CLASS-01 Randomized Clinical Trial. JAMA Surg. 2022. PMID: 34668963. doi:10.1001/jamasurg.2021.5104
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。